Evidence map›Paper›PMID 42811645›Full record

ArticleChemMedChem2026

Diethylene Glycol-Linked Ring-Fused Bis-Azoles: Target-Oriented Synthesis, In Silico Screening, and Antitumor Activity.

Sami A Al-Hussain, Abdulrahman S Alharbi, Zeinab A Muhammad, Alyaa S Abdel Halim, Magdi E A Zaki, Mark C Bagley, Refaie M Kassab

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ChemMedChem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Sami A Al-HussainDepartment of Chemistry, Faculty of Science, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh, KSA.
Abdulrahman S AlharbiDepartment of Chemistry, College of Science and Humanities-Dawadmi, Shaqra University, Sajir, Saudi Arabia.ORCID https://orcid.org/0000-0001-9379-2155
Zeinab A MuhammadDepartment of Pharmaceutical Chemistry, Egyptian Drug Authority (EDA), Giza, Egypt.ORCID https://orcid.org/0000-0003-1711-8497
Alyaa S Abdel HalimDepartment of Biochemistry, Faculty of Science, Ain Shams University, Cairo, Egypt.
Magdi E A ZakiDepartment of Chemistry, Faculty of Science, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh, KSA.ORCID https://orcid.org/0000-0002-5643-9202
Mark C BagleyDepartment of Chemistry, University of Sussex, Brighton, East Sussex, UK.ORCID https://orcid.org/0000-0003-1263-138X
Refaie M KassabDepartment of Chemistry, Faculty of Science, Cairo University, Giza, Egypt.ORCID https://orcid.org/0000-0002-8304-736X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The target-oriented synthesis of diethylene glycol-linked bis-imidazo- and bis-thiazolo ring-fused mono-, bi-, and tricyclic derivatives was accomplished using inexpensive reagents, bis-phenacyl bromide derivative 4, and thiosemicarbazone 6. The diethylene glycol-linked architectures included bis(thiazolo[3,2-a]pyrimidinone) derivatives 8a,b, bis(imidazo-azole) derivatives 12-14, bis(imidazo-thiazole) derivatives 17,18, and bis-thiazoles 20a-g. Cytotoxic evaluation against liver, lung, colon, and prostate human tumor cell lines found remarkable selectivity to hepatocellular carcinoma (HepG2) cells. The most potent bis-imidazo- and bis-thiazolo-fused derivatives 8a,b, 12 and 13 demonstrated cytotoxicity against HepG2 cells (IC

Indexed as

Antineoplastic AgentsAzolesProtein Kinase InhibitorsCell Line, TumorCell ProliferationDose-Response Relationship, DrugDrug Screening Assays, AntitumorHep G2 CellsHumansMolecular Docking SimulationMolecular StructureStructure-Activity RelationshipVascular Endothelial Growth Factor Receptor-2Antineoplastic AgentsAzolesProtein Kinase InhibitorsVascular Endothelial Growth Factor Receptor-2antitumor agentscytotoxicityfused‐ring systemsheterocyclesVEGFR‐2/FGFR‐2 inhibitors

Identifiers

PMID42811645
PMCPMC13624519

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.